Recursion Cuts Quarterly Loss To $119.0 Million, Sees Cash Lasting Into 2029

The AI drug developer's revenue hit $18.6 million on a Sanofi milestone, and it named pharma veteran Fred Hassan chair.

Share
Recursion Cuts Quarterly Loss To $119.0 Million, Sees Cash Lasting Into 2029

Recursion Pharmaceuticals, which uses artificial intelligence and automated labs to discover and develop medicines, narrowed its third-quarter net loss to $119.0 million, from $162.3 million a year earlier, and said its cash should last into 2029. The company reported the results Monday alongside a new board chair and fresh data on its lead drug candidate.

Revenue up, spending down

The loss works out to $0.22 per share, against $0.36 a year earlier. Revenue reached $18.6 million, versus $5.2 million in the third quarter of 2025, driven mainly by a $10.0 million milestone from Sanofi for an immunology small-molecule program.

Research and development spending fell to $99.1 million from $121.1 million. The company said the drop came mainly from $22.8 million of one-time in-process research costs, tied to buying full rights to its ENPP1 inhibitor REC-102 from a joint venture with Rallybio, that hit the year-earlier quarter and did not recur. General and administrative expense fell to $32.6 million from $41.6 million.

Net cash used in operations was $77.4 million, down from $117.4 million.

Cash into 2029

Cash and restricted cash stood at $561.5 million on September 30. Adding about $187.2 million in net proceeds from an underwritten offering completed October 16, pro forma cash was about $748.7 million. On current plans and with no further financing, Recursion expects that to fund it into 2029.

It reiterated 2026 cash operating expense guidance of less than $375 million and set 2027 guidance at less than $360 million. For the first nine months of 2026, that measure was $271.5 million, against $323.2 million a year earlier.

Sanofi option and a new chair

Sanofi optioned the first development candidate from its collaboration with Recursion, a potential first-in-class oral immunology drug that Sanofi plans to take into Phase 1 in 2027. The $10 million payment brings total upfront and milestone payments from Sanofi to $144 million, with more than $300 million in further milestones possible.

Recursion's board appointed Fred Hassan chair, effective October 31, expanding the board from nine to ten seats. Hassan previously ran Schering-Plough and Pharmacia, and is lead independent director at BridgeBio Pharma. Rob Hershberg said he will stay on the board.

REC-4881 polyp data

At a medical meeting in Denver, Recursion presented updated results for REC-4881 in familial adenomatous polyposis, an inherited condition with no approved drug therapies. After 12 weeks, 13 of 15 adults had less total polyp burden, with a 47% median reduction. Twelve weeks after stopping treatment, 11 of 13 evaluable patients remained below baseline.

The highest-grade treatment-related side effect was Grade 3 in four of 26 patients, with no Grade 4 or 5 events. The company anticipates starting a registrational trial in the second half of 2027, pending FDA discussions. It also reported early REC-1245 cancer data: three partial responses and an 11-of-12 disease control rate at doses of 45 mg or higher.

Recursion hosts a webinar at 8:00 a.m. ET Tuesday on the REC-4881 and REC-1245 data, and says it will give registrational trial details later this year.

Sources

More on Recursion Pharmaceuticals

All Recursion Pharmaceuticals (RXRX) coverage →